Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E. Lambrechts D, et al. Among authors: van cutsem e. Lancet Oncol. 2012 Jul;13(7):724-33. doi: 10.1016/S1470-2045(12)70231-0. Epub 2012 May 17. Lancet Oncol. 2012. PMID: 22608783
Screening for colorectal cancer.
Van Cutsem E, Tejpar S, Rutgeerts P, Janssens J. Van Cutsem E, et al. Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):397-404. Acta Gastroenterol Belg. 1995. PMID: 8775996
The molecular basis of colorectal cancer.
Tejpar S, Cassiman JJ, Van Cutsem E. Tejpar S, et al. Among authors: van cutsem e. Acta Gastroenterol Belg. 2001 Jul-Sep;64(3):249-54. Acta Gastroenterol Belg. 2001. PMID: 11680042 Review.
Molecular and genetic defects in colorectal tumorigenesis.
Tejpar S, Van Cutsem E. Tejpar S, et al. Among authors: van cutsem e. Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):171-85. doi: 10.1053/bega.2001.0279. Best Pract Res Clin Gastroenterol. 2002. PMID: 11969232 Review.
Molecular defects in colorectal tumorigenesis.
Tejpar S, van Cutsem E. Tejpar S, et al. Among authors: van cutsem e. Drugs Today (Barc). 2003;39 Suppl C:111-8. Drugs Today (Barc). 2003. PMID: 14988749 Review.
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Van Cutsem E, et al. Among authors: van de velde h. J Clin Oncol. 2004 Apr 15;22(8):1430-8. doi: 10.1200/JCO.2004.10.112. J Clin Oncol. 2004. PMID: 15084616 Clinical Trial.
Systemic treatment of pancreatic cancer.
Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C. Van Cutsem E, et al. Among authors: van steenbergen w. Eur J Gastroenterol Hepatol. 2004 Mar;16(3):265-74. doi: 10.1097/00042737-200403000-00004. Eur J Gastroenterol Hepatol. 2004. PMID: 15195889 Review.
720 results